These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 39339952)

  • 1. Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond.
    Chang JY; Balch C; Oh HS
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice.
    Gmyrek GB; Filiberti A; Montgomery M; Chitrakar A; Royer DJ; Carr DJJ
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Type I Interferon on the Safety and Immunogenicity of an Experimental Live-Attenuated Herpes Simplex Virus 1 Vaccine in Mice.
    Royer DJ; Carr MM; Chucair-Elliott AJ; Halford WP; Carr DJJ
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28122977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G.
    Stanfield BA; Bravo FJ; Dixon DA; Chouljenko VN; Kousoulas KG; Bernstein DI
    Vaccine; 2022 Oct; 40(42):6093-6099. PubMed ID: 36114130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Herpes simplex virus vaccine studies: from past to present].
    Us D
    Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses.
    Stanfield BA; Kousoulas KG; Fernandez A; Gershburg E
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.
    Ferenczy MW
    Curr Pharm Des; 2007; 13(19):1975-88. PubMed ID: 17627531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.
    Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG
    Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Varicella zoster vaccines and their implications for development of HSV vaccines.
    Gershon AA
    Virology; 2013 Jan; 435(1):29-36. PubMed ID: 23217613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of protection from live attenuated vs. sub unit HSV-2 vaccines in the guinea pig model of genital herpes: Reassessing efficacy using endpoints from clinical trials.
    Bernstein DI; Cardin RD; Pullum DA; Bravo FJ; Kousoulas KG; Dixon DA
    PLoS One; 2019; 14(3):e0213401. PubMed ID: 30917165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects and perspectives for development of a vaccine against herpes simplex virus infections.
    McAllister SC; Schleiss MR
    Expert Rev Vaccines; 2014 Nov; 13(11):1349-60. PubMed ID: 25077372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.
    Stanfield BA; Stahl J; Chouljenko VN; Subramanian R; Charles AS; Saied AA; Walker JD; Kousoulas KG
    PLoS One; 2014; 9(10):e109890. PubMed ID: 25350288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines for herpes simplex virus infections.
    Koelle DM
    Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in herpes simplex virus immunobiology and vaccine research.
    Koelle DM; Corey L
    Clin Microbiol Rev; 2003 Jan; 16(1):96-113. PubMed ID: 12525427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107
    Khan AA; Srivastava R; Vahed H; Roy S; Walia SS; Kim GJ; Fouladi MA; Yamada T; Ly VT; Lam C; Lou A; Nguyen V; Boldbaatar U; Geertsema R; Fraser NW; BenMohamed L
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of herpes simplex virus infection and pathogenesis suggest a strategy for vaccine development.
    Xu X; Zhang Y; Li Q
    Rev Med Virol; 2019 Jul; 29(4):e2054. PubMed ID: 31197909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity.
    Lauterbach H; Ried C; Epstein AL; Marconi P; Brocker T
    J Gen Virol; 2005 Sep; 86(Pt 9):2401-2410. PubMed ID: 16099897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.
    Bagley KC; Schwartz JA; Andersen H; Eldridge JH; Xu R; Ota-Setlik A; Geltz JJ; Halford WP; Fouts TR
    Viral Immunol; 2017 Apr; 30(3):178-195. PubMed ID: 28085634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.
    Awasthi S; Zumbrun EE; Si H; Wang F; Shaw CE; Cai M; Lubinski JM; Barrett SM; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
    J Virol; 2012 Apr; 86(8):4586-98. PubMed ID: 22318147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.